Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia

NCT00382109 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00382109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00382109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2007
Completion date
June 30, 2017
Enrollment
146 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell childhood acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia in remission, graft versus host disease, l1 childhood acute lymphoblastic leukemia, l2 childhood acute lymphoblastic leukemia, t-cell childhood acute lymphoblastic leukemia